

Aplasia Cutis Congenita on the Scalp

Supasuta Wongdama and Chutintorn Sriphrapadang

*Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand*

Key words: ectodermal dysplasia, fetal diseases, Graves' disease, methimazole, pregnancy, teratogenesis

INTRODUCTION

Aplasia cutis congenita is a rare condition characterized by localized absent skin at birth, often affecting the scalp. The exact pathogenesis is unclear, but it is likely related to disrupted prenatal skin development. Potential etiologies include genetic factors, trauma, intrauterine infections, teratogens, incomplete neural tube closure, and vascular compromise. We present a case of aplasia cutis congenita on the scalp potentially associated with maternal methimazole use.

A term male newborn was delivered by a 34-year-old female with a history of Graves' disease. The newborn had three well-demarcated, round lesions of absent skin on the scalp, measuring up to 1 centimeter in diameter. (Figure 1) The mother had been treated with methimazole 5 mg/day for mild Graves' hyperthyroidism. After 78 days of treatment, she tested positive for pregnancy. Methimazole was switched to propylthiouracil 50 mg/day at 9 weeks of gestation. She remained euthyroid, and propylthiouracil was discontinued at 23 weeks of gestation until delivery. The diagnosis of aplasia cutis congenita was made, potentially



Figure 1. Three well-demarcated, round scalp lesions characterized by full-thickness skin loss without involvement of the calvarium or signs of inflammation, each measuring up to 1 cm in diameter, consistent with aplasia cutis congenita on the scalp.

related to methimazole exposure, known as methimazole embryopathy. Treatment involves simple wound care, leading to healing within a few months and often leaving an atrophic scar. Large lesions or those involving the skull may require surgical reconstruction.

In this patient, with deep scalp lesions located at the midline vertex, imaging studies are indicated to assess for underlying bone defects, vascular anomalies, or brain malformations such as meningocele or porencephaly. Fortunately, the ultrasound revealed no abnormalities. Diagnosis is generally based on clinical assessment; a skin biopsy is not necessary in our case unless other lesions are suspected, and it should not be performed without prior imaging. The differential diagnosis includes conditions such as obstetric trauma from forceps, vacuum extraction, or fetal scalp monitor electrodes; infections like herpes simplex or varicella zoster; and epidermolysis bullosa. However, there is no evidence of these conditions in this case.

Current evidence does not establish a direct causal relationship between aplasia cutis congenita and methimazole use. However, antithyroid drugs should be avoided in the first trimester of pregnancy to prevent teratogenic effects, as both methimazole and propylthiouracil cross the placenta.¹ The 2017 American Thyroid Association Guidelines recommend using propylthiouracil in the first trimester and switching to methimazole in the second trimester. This approach helps mitigate the risk of hepatotoxicity associated with propylthiouracil while effectively managing hyperthyroidism, and reduces the teratogenic risks of methimazole, which can cause more severe birth defects than propylthiouracil, as major organs and systems are formed by the end of the first trimester.^{2,3} For patients with mild hyperthyroidism, propylthiouracil may be considered before conception, and antithyroid drugs can be discontinued upon confirming pregnancy if thyroid function remains normal.^{2,3}

Acknowledgments

The authors would like to express their sincere gratitude to Dr. Sidtinnon Julawukkananon for the photograph.

Ethical Consideration

The patient consent form was obtained before manuscript submission.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

CRedit Author Statement

SW: Conceptualization, Investigation, Resources, Data Curation, Writing – original draft preparation, Writing – review and editing, Visualization; **CS:** Conceptualization, Investigation, Resources, Data Curation, Writing – review and editing, Visualization, Supervision, Project Administration.

Data Availability Statement

Datasets generated and analyzed are included in the published article.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*. 2017;27(3):315-89. PMID:28056690. DOI: 10.1089/thy.2016.0457.
2. Kobaly K, Mandel SJ. Hyperthyroidism and pregnancy. *Endocrinol Metab Clin North Am*. 2019;48(3):533-45. PMID:3134552 DOI: 10.1016/j.jec.2019.05.002.
3. Agrawal M, Lewis S, Premawardhana L, Dayan CM, Taylor PN, Okosieme OE. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2022;96(6):857-68. PMID:34845757 DOI:10.1111/cen.14646.

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights; that no references have been made to predatory/suspected predatory journals; and that use of artificial intelligence (AI) or AI-assisted technologies shall be declared to include the name of the AI tool or service used; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (* optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.